JP2022505925A5 - - Google Patents
Info
- Publication number
- JP2022505925A5 JP2022505925A5 JP2021523011A JP2021523011A JP2022505925A5 JP 2022505925 A5 JP2022505925 A5 JP 2022505925A5 JP 2021523011 A JP2021523011 A JP 2021523011A JP 2021523011 A JP2021523011 A JP 2021523011A JP 2022505925 A5 JP2022505925 A5 JP 2022505925A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862754383P | 2018-11-01 | 2018-11-01 | |
| US62/754,383 | 2018-11-01 | ||
| PCT/US2019/059555 WO2020093023A1 (en) | 2018-11-01 | 2019-11-01 | Anti-tim-3 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022505925A JP2022505925A (ja) | 2022-01-14 |
| JP2022505925A5 true JP2022505925A5 (https=) | 2022-11-08 |
| JPWO2020093023A5 JPWO2020093023A5 (https=) | 2022-11-08 |
Family
ID=69159931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523011A Pending JP2022505925A (ja) | 2018-11-01 | 2019-11-01 | 抗ｔｉｍ－３抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220081480A1 (https=) |
| EP (1) | EP3873611A1 (https=) |
| JP (1) | JP2022505925A (https=) |
| CN (1) | CN113272017A (https=) |
| AU (1) | AU2019371457A1 (https=) |
| CA (1) | CA3117429A1 (https=) |
| IL (1) | IL282707A (https=) |
| WO (1) | WO2020093023A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7214440B2 (ja) * | 2018-11-01 | 2023-01-30 | 三菱重工エンジニアリング株式会社 | 検証処理装置、検証処理方法及びプログラム |
| US20240391997A1 (en) * | 2021-07-16 | 2024-11-28 | Brightpath Biotherapeutics Co., Ltd. | Anti-tim-3 antigen antibody or antibody derivative, and use thereof |
| TW202327649A (zh) * | 2021-09-15 | 2023-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｐｖｒｉｇ／ｔｉｇｉｔ結合蛋白聯合免疫檢查點抑制劑用於治療癌症 |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| KR20250034101A (ko) | 2022-07-01 | 2025-03-10 | 트랜스진 | 계면활성제-단백질-d 및 tnfsf의 구성원을 포함하는 융합 단백질 |
| WO2025202222A1 (en) | 2024-03-25 | 2025-10-02 | Institut National de la Santé et de la Recherche Médicale | Therapeutic use of sting and tlrs agonists to induce p16 expression in immune cells |
| WO2026059950A1 (en) * | 2024-09-10 | 2026-03-19 | Agilent Technologies, Inc. | Anti-human tim3 antibodies for in vitro diagnostics |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0204475A2 (en) | 2000-02-11 | 2003-04-28 | Merck Patent Gmbh | Enhancing the circulating half-life of antibody-based fusion proteins |
| AU2002248571B2 (en) | 2001-03-07 | 2007-01-18 | Merck Patent Gmbh | Expression technology for proteins containing a hybrid isotype antibody moiety |
| WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| CA3083324A1 (en) | 2010-03-05 | 2011-09-09 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| EP3099717B1 (en) | 2014-01-31 | 2019-03-27 | Novartis AG | Antibody molecules to tim-3 and uses thereof |
| US9676863B2 (en) | 2014-02-10 | 2017-06-13 | Merck Patent Gmbh | Targeted TGFβ inhibitors |
| US10259874B2 (en) * | 2014-10-27 | 2019-04-16 | Agency For Science, Technology And Research | Anti-TIM-3 antibodies |
| US20180153986A1 (en) * | 2015-04-24 | 2018-06-07 | The Brigham And Women's Hospital, Inc. | Interactions between ceacam and tim family members |
| EP3878465A1 (en) * | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| EP3370768B9 (en) * | 2015-11-03 | 2022-03-16 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
| MY200602A (en) * | 2016-07-14 | 2024-01-04 | Bristol Myers Squibb Co | Antibodies against tim3 and uses thereof |
| JOP20190013A1 (ar) * | 2016-08-25 | 2019-01-31 | Lilly Co Eli | أجسام مضادة لـ (تي آي ام -3) |
| SG11201903867YA (en) * | 2016-11-01 | 2019-05-30 | Anaptysbio Inc | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| TWI665216B (zh) * | 2016-12-29 | 2019-07-11 | 財團法人生物技術開發中心 | 抗人類tim-3抗體及其使用方法 |
| MX2019008208A (es) * | 2017-01-09 | 2019-12-11 | Tesaro Inc | Métodos para tratar el cáncer con anticuerpos anti-tim-3. |
| AU2018264455B2 (en) | 2017-05-12 | 2024-12-12 | Jiangsu Hengrui Medicine Co., Ltd. | Fusion protein containing TGF-beta receptor and medicinal uses thereof |
-
2019
- 2019-11-01 CN CN201980086657.5A patent/CN113272017A/zh active Pending
- 2019-11-01 EP EP19835889.7A patent/EP3873611A1/en not_active Withdrawn
- 2019-11-01 CA CA3117429A patent/CA3117429A1/en active Pending
- 2019-11-01 AU AU2019371457A patent/AU2019371457A1/en not_active Abandoned
- 2019-11-01 WO PCT/US2019/059555 patent/WO2020093023A1/en not_active Ceased
- 2019-11-01 JP JP2021523011A patent/JP2022505925A/ja active Pending
-
2021
- 2021-04-27 IL IL282707A patent/IL282707A/en unknown
- 2021-04-30 US US17/245,474 patent/US20220081480A1/en not_active Abandoned